Pharmac has swapped funding from nepafenac (Ilvero) to diclofenac sodium (Devatis) eye drops. Ilevro nepafenac drops were a temporary replacement for Voltaren Ophtha, for which there were supply gaps
Bringing together brilliant minds from NZ and further afield, RANZCO NZ Branch Meeting offered an abundance of new insights in ophthalmology.
Dr Peter Hadden fleshes out risks and benefits of new, promising treatments for melanomas and naevi
Chalkeyes calls for collective effort, for optometrists to stand together to gain real advocacy and reform
The desire to care for vision and enable patients to see to the best of their ability is at the heart of why most of us are working in the optical industry. Good vision isn’t just about clarity, it’s about enhancing quality of life – whether it's reading a book, driving safely or simply enjoying a b
Excellent clinical skills are not all your practice needs to stand out; connection and communication is equally important
At first glance, this appeared to be a 74-year-old man struggling with the aftermath of a transient ischaemic attack (TIA). The referral letter stated: Ocular diagnosis Right homonymous hemianopi
With more than 20 years’ experience in the optics industry, Stu Allan, licenced real estate agent and managing director of Optics NZ, said he always gets interest in buying practices from independent
The challenges of recruiting staff and attracting buyers to regional New Zealand
Following best practice in the UK and NZ, is Australia finally considering scope changes for nurses and optometrists to save vital healthcare dollars and better serve patients?
The first Eye Institute optometry seminar for 2025 eschewed the usual format of guest lecturers and quickfire presentations of unusual cases in favour of a more relaxed and entertaining wrestling matc
Creating more effective and equitable systems by embracing patient and public involvement in clinical care, education and research
